Some of Thursday's midday movers:» Read More
Baxter International Inc. rose$. 13 or. 2 percent, to $74.35. Bristol-Myers Squibb Co. rose$. 13 or. 2 percent, to $60.78. Hospira fell$. 22 or. 4 percent, to $59.88.
LONDON, Dec 8- Pfizer Inc is moving into the gene therapy space in the latest sign that the technology for fixing faulty genes may finally be ready for prime time, following earlier setbacks. The Spark program is expected to enter early-stage clinical trials for hemophilia B in the first half of 2015. Spark will be responsible for the early Phase I/II tests, with...
Dec 2- Biogen Idec Inc's research chief on Tuesday said the company is planning a late-stage trial of its experimental treatment for Alzheimer's disease after the drug cut brain plaque levels and significantly improved cognition in a small early-stage study. Brain swelling has been a recurrent issue with experimental anti-amyloid Alzheimer's drugs,...
Biogen Idec said its experimental medicine for Alzheimer's disease showed promise, prompting it to move "aggressively" into the most advanced stage of studies.
The tax inversion announcement seriously reduced the likelihood of the Pfizer AstraZeneca deal going ahead says CNBC's Catherine Boyle.
Pascal Soriot, CEO of Astrazeneca, says there will be less need for mergers and acquisitions as the company's internal drug pipeline is strong.
Discussing a possible British exit from the European Union, Pascal Soriot, CEO of Astrazeneca, says he is a believer in Europe and immigration is key to getting the best talent for his company.
Mike Ward, global director of content at SCRIP Intelligence, says pharmaceutical companies could look towards the technology sector for interesting mergers, acquisitions or partnerships.
Pfizer's bid to take over U.K. pharmaceutical company AstraZeneca would have probably "fallen apart", Pascal Soriot, the firm's CEO, told CNBC.
Pfizer's attempt to take over AstraZeneca through a $110 billion bid would have run aground on changes to U.S. tax laws, even if the companies had reached a deal.
Some of the names on the move ahead of the open.
American pharmaceutical giant has been pursuing AstraZeneca for some time, however CNBC's Catherine Boyle says it looks like the deal has "definitely receded".
Pfizer’s $110 billion bid for AstraZeneca was one of the biggest business stories of 2014 – so could a new bid be one of the biggest stories in 2015?
Pfizer has seen off its six month cooling period before it can launch another bid for AstraZeneca, but will the American drugs giant continue its pursuit?
Before you get too excited about Friday's move, "Mad Money" host Jim Cramer puts it in context.
Nov 20- The U.S. Food and Drug Administration has approved a long-acting narcotic painkiller with abuse-resistant properties made by Purdue Pharma L.P., the agency said on Thursday. The FDA approved the once-daily drug, Hysingla ER, with the expectation that it will reduce, though not necessarily prevent, abuse through snorting or injecting.
*AstraZeneca designates oncology as new growth driver. LONDON, Nov 18- AstraZeneca touted an "industry-leading" line-up of hot new cancer drugs on Tuesday, aiming to show investors it has a strong independent future just days before takeover rules would allow Pfizer to launch a new bid. AstraZeneca, which saw off a $118 billion approach from Pfizer in May, is his...
*AstraZeneca designates oncology as new growth driver. LONDON, Nov 18- AstraZeneca touted an "industry-leading" line-up of hot new cancer drugs at an investor day on Tuesday, aiming to show it has a strong independent future after seeing off a $118 billion bid from Pfizer in May. AstraZeneca is his biggest holding.
AstraZeneca said it had made good progress in developing a pipeline of new drugs.
*Investor day comes 8 days before Pfizer can resume pursuit. LONDON, Nov 18- AstraZeneca, determined to show it has a strong independent future after seeing off a $118 billion bid from Pfizer in May, said it had made good progress in developing a pipeline of new drugs. It reiterated it was on course to return to growth and that annual sales would rise by three quarters...